Zobrazeno 1 - 10
of 716
pro vyhledávání: '"M, Grivaux"'
Publikováno v:
La Revue de medecine interne. 42(8)
Publikováno v:
La Revue De Médecine Interne
La Revue De Médecine Interne, Elsevier, 2021, ⟨10.1016/j.revmed.2021.03.010⟩
La Revue De Médecine Interne, Elsevier, 2021, ⟨10.1016/j.revmed.2021.03.010⟩
The present article details the publication process and the vicissitudes of three articles about SARS-CoV-2 and its related disease (COVID-19). The three articles were published one month apart between March and May 2020. Their mediatization led Fren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53d03fc9c0c0be5580c1f70b3cae1b78
https://hal-univ-paris.archives-ouvertes.fr/hal-03252084
https://hal-univ-paris.archives-ouvertes.fr/hal-03252084
Publikováno v:
La Revue de Médecine Interne. 42:593
Publikováno v:
La Revue De Medecine Interne
Autor:
O. Molinier, Francis Martin, S. Lacroix, F. Goupil, D. Debieuvre, J.-B. Auliac, S. Jeandeau, M. Grivaux
Publikováno v:
Respiratory medicine and research. 77
To estimate five-year survival in non-small-cell lung cancer (NSCLC) patients according to histology and to identify independent prognostic factors by histology.Data were obtained during the KBP-2010-CPHG study, which included all new cases of primar
Autor:
D. Herman, B. Gentil le Pecq, P. Thomas, Didier Debieuvre, J.R. Barrière, J.-P. Vabre, C. Clarot, M. Grivaux, B. Asselain, Y. Duval
Publikováno v:
Respiratory medicine and research. 76
Background Patients with metastatic non-small-cell lung cancer (NSCLC) who survive more than 2 years are considered long-term survivors (LTSs). The present study examined factors associated with long-term survival and collected information for future
Autor:
M, Grivaux
Publikováno v:
Revue de pneumologie clinique. 74(6)
Autor:
D, Debieuvre, L, Moreau, M, Coudert, C, Locher, B, Asselain, D, Coëtmeur, C, Dayen, F, Goupil, F, Martin, P, Brun, G, De Faverges, P-A, Hauss, S, Gally, B, Ben Hadj Yahia, M, Grivaux
Publikováno v:
Revue des maladies respiratoires. 36(6)
The benefit of tyrosine kinase inhibitors for patients with an EGFR wild-type non-small cell lung cancer (NSCLC) remains controversial.The survival of patients with an EGFR wild-type NSCLC who received second- or third-line erlotinib treatment was as
Autor:
M Grivaux
Publikováno v:
Revue de Pneumologie Clinique. 74:365-366
Autor:
F, Pinquié, F, Goupil, J-P, Oster, A, Dixmier, P-A, Renault, A, Lévy, J-P, Mathieu, N, Paillot, F C, Goutorbe, P, Masson, O, Molinier, D, Debieuvre, M, Grivaux
Publikováno v:
Revue des maladies respiratoires. 34(9)
The aim of ESCAP-2011-CPHG, promoted by the French College of General Hospital Respiratory Physicians, was to describe therapeutic strategies in lung cancer in the first 2 years after diagnosis, in a real-life setting. This article focuses on patient